Regeneron posts update on its muscle-sparing approach, a new quadruple agonist emerges at #EASD25news2025-09-19T11:20:28+00:00September 19th, 2025|Endpoints News|
Laura Shawver finds her next big bet; Sangamo CFO hands in resignationnews2025-09-19T11:00:34+00:00September 19th, 2025|Endpoints News|
FDA rescinds lab-developed test rule after court ordernews2025-09-18T19:07:44+00:00September 18th, 2025|Endpoints News|
Rare pediatric voucher reauthorization again advances out of House committeenews2025-09-18T17:57:50+00:00September 18th, 2025|Endpoints News|
Replimune’s stock sinks on rocky path forward for cancer treatmentnews2025-09-18T16:54:56+00:00September 18th, 2025|Endpoints News|
Telehealth advertising comes under FDA scrutinynews2025-09-18T15:37:00+00:00September 18th, 2025|Endpoints News|
Logistics real estate company Prologis promises £3.9B in UK life sciences investmentnews2025-09-18T14:51:31+00:00September 18th, 2025|Endpoints News|
Nektar’s stock rallies on eczema data; Novo to lay off 263 workers in NJnews2025-09-18T14:47:51+00:00September 18th, 2025|Endpoints News|
Pfizer, Arvinas to sell rights to lead PROTAC one month after filing for FDA reviewnews2025-09-18T14:14:45+00:00September 18th, 2025|Endpoints News|
Shape Therapeutics strikes AAV capsid deal with VectorY worth up to $1.2Bnews2025-09-18T13:45:49+00:00September 18th, 2025|Endpoints News|
